Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.68 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.68 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.68 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12824581 | 0.81 | AGTR1 (0.82) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL4026 | 0.81 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL4025 | 0.81 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9122330 | 0.81 | AGTR1 (0.81) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9122343 | 0.81 | AGTR1 (0.81) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1815060 | 0.81 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL156290 | 0.81 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL7405236 | 0.80 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 | |
| SCHEMBL22856162 | 0.80 | AGTR1 (0.89) | AGTR1ABCC3ABCC2 | |
| Eprosartan SCHEMBL1119965 | 0.80 | AGTR1 (0.98) | AGTR1ABCC3ABCC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160834-A1 | Combination therapy for the treatment of hypertension | MERCK & CO., INC. | 2006-07-20 | — | — | US | disclosed |
| US-20040116510-A1 | Antihypertensive agent and cholesterol absorption inhibitor combination therapy | NICHTBERGER STEVEN A (US) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160834-A1 | Combination therapy for the treatment of hypertension | FABP4, GPR119, HMGCR | AGTR1 51/4885ABCC3 634/4885ABCC2 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.